SILVERARC CAPITAL MANAGEMENT LLC
Q1 2025 Form 13-F
BOSTON, MASSACHUSETTS
CIK 0001816307
· CRD 304220
· SEC-registered investment adviser
Consolidated report · includes
1 manager
since Q4 2020
$489.0M Reported Value Total
SILVERARC CAPITAL MANAGEMENT, LLC reports 7 total accounts under management (AUM). There are 7 discretionary accounts valued at $1,037,407,671, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
3 funds
· $935.3M gross asset value
Hedge Fund: $913.6M · Venture Capital Fund: $21.7M
Source: Form ADV filed 2026-03-30
Reported value
$489.0M
Quarter over quarter
-8.0%
Holdings
67
Top-10 concentration
49.3%
Filing Structure
Reports holdings for
- SILVERARC CAPITAL LLC · File #028-20993 · since Q4 2020
Key People
Form ADV owners & control persons
Devesh Sharad Gandhi
FOUNDER & CHIEF EXECUTIVE OFFICER
Paul Nmn Brauer
CHIEF COMPLIANCE OFFICER
Amanda Lynn Goodell
CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2025 13F record
Q1 2025 13F filing summary
| Period of report | March 31, 2025 |
|---|---|
| Filed | May 14, 2025 |
| Form | 13F-HR |
| Reported value | $489.0M |
| Positions | 67 |
| Change in reported value | +7.0% |
| New positions | 23 |
| Exited positions | 14 |
| Position turnover | 45.7% |
| Top-10 concentration | 49.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 12, 2026
|
63 | $854.4M |
|
Q2 2026 13F
Filed Aug 13, 2026
|
65 | $962.2M |
|
Q1 2026 13F
Filed May 14, 2026
|
67 | $979.8M |
|
Q4 2025 13F
Filed Feb 12, 2026
|
64 | $720.1M |
|
Q3 2025 13F
Filed Nov 12, 2025
|
73 | $741.6M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
57 | $542.3M |
|
Q1 2025 13F
Filed May 14, 2025
|
67 | $489.0M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
58 | $457.2M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
68 | $445.3M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
66 | $423.9M |
|
Q1 2024 13F
Filed May 15, 2024
|
73 | $360.1M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
64 | $336.0M |
|
Q3 2023 13F
Filed Nov 13, 2023
|
68 | $329.8M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
77 | $323.3M |
|
Q1 2023 13F
Filed May 15, 2023
|
67 | $242.3M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
81 | $349.6M |
|
Q3 2022 13F
Filed Oct 28, 2022
|
68 | $295.6M |
|
Q2 2022 13F
Filed Jul 25, 2022
|
59 | $324.8M |
|
Q1 2022 13F
Filed May 13, 2022
|
65 | $241.6M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
68 | $246.8M |
4 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q1 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | VRNA VERONA PHARMA PLC | $34.7M | 7.09% |
| 2 | MRUS MERUS N V | $34.1M | 6.98% |
| 3 | NUVL NUVALENT INC | $31.1M | 6.37% |
| 4 | AKRO AKERO THERAPEUTICS INC | $29.1M | 5.96% |
| 5 | INSM INSMED INC | $24.5M | 5.01% |
| 6 | KALV KALVISTA PHARMACEUTICALS INC | $19.6M | 4.01% |
| 7 | VCYT VERACYTE INC | $18.8M | 3.84% |
| 8 | RYTM RHYTHM PHARMACEUTICALS INC | $17.9M | 3.66% |
| 9 | SNDX SYNDAX PHARMACEUTICALS INC | $16.1M | 3.29% |
| 10 | URGN UROGEN PHARMA LTD | $15.3M | 3.12% |
| 11 | RNA AVIDITY BIOSCIENCES INC | $12.1M | 2.48% |
| 12 | SLNO SOLENO THERAPEUTICS INC | $11.9M | 2.43% |
| 13 | ASND ASCENDIS PHARMA A/S | $11.8M | 2.41% |
| 14 | IRON DISC MEDICINE INC | $11.7M | 2.4% |
| 15 | ORIC ORIC PHARMACEUTICALS INC | $11.5M | 2.35% |
| 16 | ETNB 89BIO INC | $11.0M | 2.25% |
| 17 | ERAS ERASCA INC | $10.1M | 2.06% |
| 18 | WVE WAVE LIFE SCIENCES LTD | $8.5M | 1.74% |
| 19 | NBIX NEUROCRINE BIOSCIENCES INC | $8.0M | 1.64% |
| 20 | TVTX TRAVERE THERAPEUTICS INC | $7.3M | 1.5% |
Values as reported on the Q1 2025 Form 13F. Every position is in the holdings table below.